Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism

Table 2 Demographic patient data and blood count of healthy donors and patients with localized disease and metastasized disease

	Healthy controls (n = 17)	G1 (localized disease) (n = 3)	G2 (localized disease) (n = 8)	G3 (localized disease) (n = 9)	Metastasized disease (M1) (n = 19)	p-value G1 vs G3 (localized disease)	p-value G2 vs G3 (localized disease)	p-value controls vs G2 (localized disease)	p-value controls vs G3 (localized disease)	p-value controls vs M1 (metastasized disease)
Age (years)	48.0 ± 10.0	48.7 ± 6.9	63.7 ± 11.4	56.7 ± 13.7	54.8 ± 12.4	0.3904	0.1190	0.0027	0.0875	0.0873
BMI (kg/m²)	24.2 ± 3.4	22.6 ± 3.3	24.7 ± 3.0	25.4 ± 2.6	24.4 ± 4.4	0.2872	0.9434	0.7498	0.4440	0.9049
Hb (g/dl)	14.6 ± 1.0	14.1 ± 1.0	12.4 ± 2.4	13.3 ± 1.7	12.0 ± 1.8	0.5022	0.7927	0.0041	0.0285	< 0.0001
Platelets (th/μl)	227.3 ± 45.5	225.3 ± 46.2	310.4 ± 116.4	289.9 ± 93.7	293.2 ± 140.8	0.3423	0.4906	0.0222	0.0461	0.0828
Leukocytes (th/μl)	5.8 ± 1.2	6.9 ± 0.8	7.5 ± 2.7	7.3 ± 2.0	7.85 ± 5.5	0.7512	0.3619	0.0401	0.0299	0.1524

Demographic patient data (age, BMI) and blood counts (hemoglobin (Hb), platelet and leukocyte counts) of patients with localized disease (G1, G2 and G3) and metastasized disease (M1). Data are presented as mean value ± standard deviation (SD). p-values were determined using Student’s t-tests for independent samples. p-values <0.05 are marked in bold

ISSN: 1471-2407